🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Tenofovir Alafenamide Taficita 200Mg /25Mg Tablets

$70.00$2.33 per tablet · 30 tablets
Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in discreet packaging with a tracking number. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email order@pharmeasybank.com.

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

What Is Taficita 200 mg/25 mg?

Taficita 200 mg/25 mg is described as an oral antiretroviral combination containing emtricitabine and tenofovir alafenamide (TAF).

Both ingredients belong to the nucleoside/nucleotide reverse transcriptase inhibitor class of HIV medicines.

These medicines work by interfering with an enzyme called reverse transcriptase, which HIV needs to reproduce inside human cells.

Emtricitabine and tenofovir alafenamide are converted into active forms inside cells. Their active metabolites interfere with the production of viral DNA, preventing HIV from completing an essential stage of its replication process.

This helps reduce viral replication when the combination is used as part of an effective antiretroviral treatment regimen.

For HIV-1 treatment, emtricitabine/tenofovir alafenamide must be combined with other appropriate antiretroviral medicines. It is not a complete HIV treatment regimen by itself.

The same combination is also approved in certain countries for HIV-1 pre-exposure prophylaxis (PrEP) in eligible HIV-negative individuals.

PrEP is a preventive strategy that reduces the risk of acquiring HIV when used correctly and accompanied by regular medical monitoring.

How Does Taficita 200 mg/25 mg Work?

1. Contains Two Antiretroviral Ingredients

The described formulation combines emtricitabine and tenofovir alafenamide.

Both target the reverse transcriptase enzyme used by HIV.

2. Inhibits HIV Reverse Transcriptase

Reverse transcriptase is an enzyme that HIV uses to convert its RNA into DNA.

The active metabolites of both medicines interfere with this process.

3. Prevents Viral DNA Formation

The active compounds become incorporated into viral DNA and terminate further DNA chain elongation.

4. Reduces Viral Replication

By disrupting viral DNA synthesis, the combination helps limit HIV replication.

5. Supports Viral Suppression

When combined with other effective antiretroviral medicines, the formulation can contribute to reducing HIV viral load.

6. Supports Immune Health

Successful HIV treatment can help preserve or improve immune function over time.

7. Provides an HIV Prevention Option

Where approved, the combination may be used as PrEP in eligible HIV-negative individuals.

8. Uses a Tenofovir Prodrug

Tenofovir alafenamide is converted intracellularly into tenofovir and then its active diphosphate metabolite.

Compared with tenofovir disoproxil fumarate, TAF generally produces lower circulating tenofovir exposure at approved doses, which can reduce certain kidney and bone-related adverse effects.

However, kidney and bone risks are not eliminated.

Uses of Taficita 200 mg/25 mg

1. HIV-1 Infection Treatment

Emtricitabine/tenofovir alafenamide is used as part of combination antiretroviral therapy for HIV-1 infection.

It must be combined with other appropriate antiretroviral medicines.

2. HIV Viral Load Suppression

When used in an effective combination regimen, the medicine helps suppress HIV replication and reduce viral load.

3. Supporting Immune Function

Successful antiretroviral treatment can help maintain immune function and reduce the risk of HIV-related complications.

4. HIV-1 Pre-Exposure Prophylaxis (PrEP)

In jurisdictions where this formulation is approved for PrEP, it may be prescribed to eligible HIV-negative individuals at risk of acquiring HIV.

For example, the US-approved emtricitabine/TAF PrEP indication excludes individuals at risk from receptive vaginal sex because effectiveness for that exposure route has not been established.

5. Long-Term HIV Management

The combination can serve as part of a long-term antiretroviral regimen when clinically appropriate.

6. Selected Patients Requiring a TAF-Based Regimen

A healthcare professional may consider a TAF-containing regimen when evaluating renal health, bone health, previous treatment and other clinical factors.

7. Combination Antiretroviral Therapy

Emtricitabine/TAF is commonly paired with another active antiretroviral medicine to create a complete HIV treatment regimen.

Effective combination antiretroviral treatment helps reduce the risk of complications associated with uncontrolled HIV infection.

How to Take Taficita 200 mg/25 mg

Taficita should be taken according to the prescribing healthcare professional’s instructions.

General Administration Instructions

  1. Confirm the active ingredients and strength on the packaging.
  2. Take the medicine according to the prescribed schedule.
  3. Swallow the tablet with water.
  4. Follow any food-related instructions provided with the product.
  5. Take the medicine consistently to maintain effective drug exposure.
  6. Do not stop or interrupt treatment without medical advice.
  7. Inform the healthcare professional about other medicines and supplements.
  8. Attend regular HIV testing and laboratory monitoring appointments.
  9. Report unusual symptoms or serious adverse reactions.
  10. Store the medicine according to the original product labeling.

Can Taficita Be Taken Once Daily?

The emtricitabine 200 mg/TAF 25 mg combination is generally administered once daily in applicable approved regimens.

The exact schedule should follow the prescription.

Can Taficita Be Taken With Food?

This combination can generally be taken with or without food.

However, other medicines in a complete HIV treatment regimen may have specific food requirements.

Can Taficita Be Taken Alone for HIV Treatment?

No.

Emtricitabine/TAF is not a complete HIV treatment regimen.

It must be used with other appropriate antiretroviral medicines.

Can Taficita Be Used for PrEP?

The emtricitabine/TAF combination is approved for PrEP in some jurisdictions and for specified populations.

The actual Taficita brand must have an applicable regulatory indication before it is advertised for PrEP.

What If a Dose Is Missed?

Follow the manufacturer’s missed-dose instructions or contact the prescribing healthcare professional.

Do not double doses to compensate for a missed tablet.

How Long Does Taficita Take to Work?

The clinical response depends on whether the medicine is being used for HIV treatment or prevention.

After Administration

Both ingredients are absorbed and converted into their active intracellular metabolites.

During the First Several Weeks of HIV Treatment

When combined with an effective antiretroviral regimen, HIV viral load generally begins to decrease.

Over the Following Months

Many patients achieve substantial viral suppression with consistent, effective treatment.

The time required depends on baseline viral load, adherence, resistance and other factors.

During PrEP Use

Protection depends on consistent administration, the exposure route and sufficient time to reach protective drug levels.

The onset of protection for every exposure route has not been established for emtricitabine/TAF.

Common Side Effects

Possible side effects include:

  • Headache
  • Nausea
  • Diarrhea
  • Abdominal discomfort
  • Fatigue
  • Dizziness
  • Changes in body weight
  • Changes in cholesterol levels
  • Mild gastrointestinal symptoms

Not every patient experiences these effects, and the safety profile depends on other medicines used in the regimen.

Serious Side Effects

Seek medical attention if any of the following occur:

  • Severe allergic reactions
  • Significant kidney problems
  • Severe or persistent vomiting
  • Unusual weakness
  • Severe abdominal pain
  • Yellowing of the skin or eyes
  • Symptoms of lactic acidosis
  • Signs of worsening hepatitis B after discontinuation
  • Severe unexplained fatigue
  • Significant reduction in urine output

Important Serious Risks

Hepatitis B Exacerbation: Stopping emtricitabine/TAF in patients with hepatitis B infection may lead to severe acute hepatitis B exacerbations.

Kidney Problems: Tenofovir-containing medicines may cause renal complications, including rare serious kidney injury.

Lactic Acidosis: Rare but potentially life-threatening lactic acidosis has been associated with nucleoside analogue medicines.

Liver Problems: Severe liver complications may occur, particularly in patients with underlying liver disease.

Drug Resistance: Inconsistent treatment or inappropriate use may contribute to antiretroviral resistance.

Undiagnosed HIV During PrEP: Starting or continuing PrEP in a person with unrecognized HIV infection can promote resistance because the two-drug combination is not sufficient HIV treatment.

Contraindications & Precautions

1. Allergy to Active Ingredients

Patients with serious hypersensitivity to emtricitabine, tenofovir alafenamide or formulation ingredients should not use the medicine.

2. HIV Status Before PrEP

A confirmed HIV-negative status is required before starting PrEP.

Testing should also evaluate possible acute HIV infection.

3. Regular HIV Testing During PrEP

Ongoing HIV testing is essential during PrEP use.

4. Hepatitis B Infection

Both emtricitabine and tenofovir have activity against hepatitis B virus.

Discontinuation can cause severe hepatitis B flare-ups in infected patients.

5. Kidney Disease

Renal function should be evaluated before and during treatment as indicated.

6. Liver Disease

Patients with significant liver disease require appropriate medical assessment.

7. Pregnancy

Use during pregnancy should be based on current clinical guidance, the indication and individual risk-benefit assessment.

8. Breastfeeding

Recommendations depend on HIV status, treatment indication, infant exposure and local clinical guidelines.

9. Drug Interactions

Certain medicines can reduce TAF exposure or increase toxicity.

Important examples include:

  • Rifampicin
  • Carbamazepine
  • Phenytoin
  • Phenobarbital
  • St. John’s wort
  • Certain antiviral medicines
  • Medicines affecting renal function

10. Antiretroviral Resistance

Inappropriate use or inconsistent dosing may contribute to resistance.

11. Bone Health

TAF generally has a more favorable bone safety profile than TDF, but bone-related effects remain relevant in selected patients.

12. Lipid Changes

TAF-containing regimens may be associated with changes in cholesterol and other lipid parameters.

13. Weight Changes

Weight changes may occur during antiretroviral treatment, although effects cannot always be attributed to this combination alone.

14. Immune Reconstitution

Patients beginning effective HIV treatment may develop inflammatory symptoms related to immune reconstitution.

15. Coinfections

Hepatitis B, hepatitis C, tuberculosis and other infections may affect treatment decisions.

16. PrEP Limitations

PrEP does not prevent all sexually transmitted infections and does not protect against pregnancy.

17. Post-Exposure Prophylaxis

A person with a recent possible HIV exposure should seek urgent medical evaluation for PEP rather than starting this medicine independently.

PEP should generally begin as soon as possible and no later than 72 hours after exposure.

18. Medical Monitoring

Healthcare professionals may assess:

  • HIV testing
  • HIV viral load during treatment
  • CD4 count when indicated
  • Renal function
  • Serum creatinine
  • Estimated creatinine clearance
  • Urine protein or glucose when indicated
  • Hepatitis B status
  • Liver function
  • Medication adherence
  • Drug interactions
  • Lipid levels
  • Treatment response
  • Antiretroviral resistance
  • PrEP eligibility
  • Pregnancy status when applicable
  • Symptoms of acute HIV infection
  • Potential adverse reactions

Potential Therapeutic Advantages

  • Dual Antiretroviral Ingredients.
  • Reverse Transcriptase Inhibition.
  • HIV-1 Replication Suppression.
  • Oral Tablet Formulation.
  • Once-Daily Administration in Applicable Regimens.
  • Combination Antiretroviral Therapy Component.
  • Established HIV Treatment Application.
  • Selected HIV Prevention Application.
  • TAF-Based Tenofovir Delivery.
  • Lower Systemic Tenofovir Exposure Compared With TDF.
  • Generally Improved Renal and Bone Safety Markers Compared With TDF.
  • Long-Term HIV Management Support.
  • Laboratory-Guided Treatment Monitoring.

Disadvantages / Limitations

  • Not a Complete HIV Treatment Regimen.
  • Does Not Cure HIV.
  • Requires Consistent Administration.
  • Potential Kidney Complications.
  • Potential Liver Complications.
  • Hepatitis B Flare Risk After Discontinuation.
  • Possible Lactic Acidosis.
  • Potential Drug Interactions.
  • Possible Nausea.
  • Possible Diarrhea.
  • Possible Headache.
  • Possible Lipid Changes.
  • Potential Antiretroviral Resistance.
  • Requires HIV Testing During PrEP.
  • PrEP Eligibility Restrictions.
  • Does Not Prevent Other Sexually Transmitted Infections.
  • Does Not Replace PEP After Recent Exposure.
  • Requires Medical Supervision.
  • Requires Laboratory Monitoring.
  • Country-Specific Regulatory Restrictions.

Important Notes

Brand Name: Taficita.

Generic Combination: Emtricitabine + Tenofovir Alafenamide.

Strength: 200 mg/25 mg.

Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.

Therapeutic Category: Antiretroviral / HIV Medicines.

Mechanism of Action: HIV Reverse Transcriptase Inhibition.

Route: Oral.

HIV Treatment: Requires Other Antiretroviral Medicines.

PrEP: Only Where Approved and Clinically Appropriate.

Typical Frequency: Once Daily.

Major Warning: Hepatitis B Exacerbation After Discontinuation.

Kidney Monitoring: Required as Clinically Indicated.

HIV Testing: Essential for PrEP.

Pregnancy: Individualized Medical Assessment.

Breastfeeding: Follow Specialist Guidance.

Drug Interactions: Important.

Prescription Status: Prescription Medicine.

Storage: Follow Original Product Labeling.

Frequently Asked Questions

1. What is Taficita 200 mg/25 mg used for?

The emtricitabine/TAF combination is used as part of HIV-1 treatment and, where approved, for HIV-1 pre-exposure prophylaxis in eligible individuals.

2. What are the active ingredients in Taficita?

The described 200 mg/25 mg formulation contains emtricitabine 200 mg and tenofovir alafenamide 25 mg. Confirm this against the original Taficita packaging.

3. Is Taficita an antiretroviral medicine?

Yes, if the stated combination is confirmed. Both ingredients are antiretroviral medicines belonging to the NRTI class.

4. How does Taficita work?

It interferes with HIV reverse transcriptase and prevents normal viral DNA synthesis.

5. Can Taficita cure HIV?

No. Antiretroviral treatment can suppress HIV replication but does not cure HIV infection.

6. Can Taficita be used alone for HIV treatment?

No. Emtricitabine/TAF must be combined with other appropriate antiretroviral medicines for HIV treatment.

7. Can Taficita be used for HIV prevention?

The combination is approved for PrEP in certain jurisdictions and populations. Brand-specific approval and eligibility must be verified.

Product DetailsInformation
Product NameTaficita 200 mg/25 mg Tablets
Brand NameTaficita
Generic NameEmtricitabine + Tenofovir Alafenamide
Active IngredientsEmtricitabine 200 mg + Tenofovir Alafenamide 25 mg
Strength200 mg/25 mg
Dosage FormOral Film-Coated Tablet – Verify Packaging
Drug ClassNucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Therapeutic CategoryAntiretroviral / HIV Medicines
Primary UsesHIV-1 Treatment in Combination With Other Antiretrovirals; HIV-1 Pre-Exposure Prophylaxis Where Approved
Mechanism of ActionInhibition of HIV Reverse Transcriptase
Route of AdministrationOral
Dosage FrequencyGenerally Once Daily, as Prescribed
Treatment DurationDepends on HIV Treatment or Prevention Plan
ManufacturerVerify Original Packaging
Pack SizeVerify Original Packaging
Prescription StatusPrescription Medicine
StorageFollow Manufacturer Instructions
Medical SupervisionHIV Specialist or Qualified Healthcare Professional
Pack sizes30 tablets, 60 tablets, 90 tablets, 120 tablets, 150 tablets, 300 tablets
Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.